Nedostatak vitamina D, zamor i perzistentni kašalj su nezavisni prediktori depresivnih simptoma kod pacijenata sa sarkoidozom

  • Branislav Gvozdenovic PPD Serbia, Part of Thermo Fisher Scientific, Pharmacovigilance Department, Belgrade
  • Violeta Mihailovic-Vucinic Opšta bolnica MediGroup, Beograd, Srbija
  • Mira Vukovic Zdravstveni centar Valjevo, Srbija https://orcid.org/0000-0002-3662-5374
  • Maja Omcikus Medicinski fakultet Univerziteta u Beogradu, Srbija; Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija
  • Jelena Cvejic Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija
  • Slobodan Belic Medicinski fakultet Univerziteta u Beogradu, Srbija; Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija
  • Jelena Jankovic Medicinski fakultet Univerziteta u Beogradu, Srbija; Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija https://orcid.org/0000-0001-8529-8624
  • Natasa Djurdjevic Medicinski fakultet Univerziteta u Beogradu, Srbija; Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija
  • Mihailo Stjepanovic Medicinski fakultet Univerziteta u Beogradu, Srbija; Klinika pulmologiju Univerzitetskog kliničkog centra Srbije, Beograd, Srbija https://orcid.org/0000-0003-1787-1438
DOI: https://doi.org/10.5937/jomb0-54015
Ključne reči: Sarkoidoza, Depresivni simptomi, Nedostatak Vitamina D, Zamor, Kašalj, Multivarijantna analiza

Sažetak


Uvod: Depresivni simptomi su česti u sarkoidozi. Procenjivali smo uticaj simptoma sarkoidoze, plućne funkcije, zamora, radiografskih nalaza, komorbiditeta, lečenja i serumskog nivoa 25-hidroksivitamina D (25(OH)D) na depresivne simptome pacijenata sa sarkoidoom.

Metode: U studiji preseka smo merili depresivne simptome korišćenjem Skale depresije Centra za epidemiološke studije (CES-D) i zamor pomoću Skale za procenu zamora (engl. Fatigue Assessment Scale, FAS). Prisustvo depresivnih simptoma je difinisano CES-D skorovima ≥16 ili ≥20. Zamor je utvrđem FAS skorom ≥22.

Rezultati: Studijom je ukupno obuhvaćeno 400 pacijenata. CES-D skor ≥16 imalo je 128 pacijenata, a CES-D skor ≥20 njih 86. Multivarijantnim binominalnim logističkim regresionim modelom utvrđeni su sledeći nezavisni prediktori CES-D skora ≥16: ženski pol (OR 1.983), hronični tok sarkoidoze (OR 2.311), serumski nivoi 25(OH)D ≤20 ng/mL (OR 2.326), persistentni suvi kašalj (OR 2.173), FAS skor ≥22 (OR 9.243), i radiološki stadijum grudnog koša 3 (8.851). Pet varijabli predstavljalo je nezavisne prediktore za CES-D skor ≥20: diplopija (OR 4.411), FEV1 <80% predviđene vrednosti udružen sa FVC <80% predviđene vrednosti (OR 2.311), serumski nivoi 25(OH)D ≤20 ng/mL (OR 2.278), persistentni suvi kašalj (OR 3.001), i skorovi FAS ≥22 (OR 7.611).

Zaključak: Merenje doprinosa uticaja niskog nivoa 25-hidroksivitamina D u serumu i uticaja perzistentnog suvog kašlja na depresivne simptome kod pacijenata sa sarkoidozom može biti kljućno u donošenju odluke o primeni vitamina D3 samostalno ili zajedno sa antitusicima, pre postavljanja psihijatrijske dijagnoze depresije i uvođenja terapije antidepresivima.

Reference

1. Victorson DE, Cella D, Judson MA. Quality of life evaluation in sarcoidosis: current status and future directions. Curr Opin Pulm Med 2008; 14 (5): 470–7.
2. Drent M, Jessurun NT, Wijnen PA, Bekers O, Bast A. Drug-induced comorbidities in patients with sarcoidosis. Curr Opin Pulm Med 2022; 28 (5): 468–77.
3. Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager Jr H, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163 (2): 329–34.
4. Hinz A, Brahler E, Mode R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (2): 139–46.
5. Sikjær MG, Hilberg O, Farver-Vestergaard I, Ibsen R, Løkke A. Risk of depression and anxiety in 7.302 patients with sarcoidosis: A nationwide cohort study. Sarcoidosis Vasc Diffuse Lung Dis 2024; 41 (1): e2024009.
6. de Kleijn WPE, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol 2016; 18 (2): 439–52.
7. Mihailovic-Vucinic V, Ignjatovic S, Dudvarski-Ilic A, Stjepanovic M, Vukovic M, Omcikus M, et al. The role of vitamin D in multisystem sarcoidosis. J Med Biochem 2012; 31: 339–46.
8. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911–30.
9. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas 1977; 1 (3): 385–401. doi.org/10.1177/014662167700100306.
10. Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 2011; 29 (4): 413–20.
11. Kato N, Kinugawa K, Shiga T, Hatano M, Takeda N, Imai Y, et al. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. J Cardiol 2012; 60 (1): 23–30.
12. Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J Affect Disord 2012; 136 (3): 789–96.
13. Vucinic V, Filipovic S, Zugic V, Videnovic J, Gvozdenovic B. Depression in sarcoidosis - CES-D scale in sarcoidosis patients (Abstract) CHEST 2007 Scientific Highlights: Abstracts of Original Investigations and Case Reports, October 20-25, 2007, Chicago, IL. Chest 2007; 132 (4 Suppl): 586S–7S.
14. Weissman M, Sholomskas D, Pottenger M, Prusoff B, Locke B. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106 (3): 203–14.
15. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): A systematic review with meta-analysis. PloS One 2016; 11 (5): e0155431.
16. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale (FAS). J Psychosom Res 2003; 54: 345–52.
17. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K. Examination of the dimensionality of fatigue: the construction of the Fatigue Assessment Scale (FAS). Eur J Psychol Assess 2004; 20 (1): 39–48.
18. Michielsen HJ, De Vries J, Drent M, Peros-Golubicic T. Psychometric qualities of the Fatigue Assessment Scale in Croatian sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (2): 133–8.
19. Drent M, Lower EE, De Vries K. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40 (1): 255–3.
20. Gvozdenovic BS, Mihailovic-Vucinic VV, Vukovic MH, Stjepanovic MI, Buha I, Mihailovic SV, et al. Predictors of cough-specific and generic quality of life in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 158–68.
21. Stjepanovic M, Mihailovic-Vucinic V, Gvozdenovic BS, Milin-Lazovic J, Belic S, Djurdjevic N, et al. King’s Sarcoidosis Questionnaire (KSQ) – Validation study in Serbian speaking population of sarcoidosis patients. PLoS One 2023; 18 (9): e0273126. doi: 10.1371/journal.pone.0273126.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–38.
23. Baughman RP, Papanikolaou I. Current concepts regarding calcium metabolism and bone health in sarcoidosis. Curr Opin Pulm Med 2017; 23 (5): 476–81.
24. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic–Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102 (11): 1636–42.
25. De Vries J, Rothkrantz-Kos S, Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (2): 127–36.
26. Mokros L, Miłkowska-Dymanowska J, Gwadera L, Pietras T, Piotrowski W. Chronotype and the Big-Five personality traits as predictors of chronic fatigue among patients with sarcoidosis. A cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis 2023; 40 (2): e2023018.
27. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J 1961; 2 (5261): 1165–72.
28. Levy A, Hamzeh N, Maier LA. Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis? F1000Research 2018; 7: F1000 Faculty Rev-600. doi: 10.12688/f1000research.11068.1.
29. Kovacova E, Vysehradsky R, Kocan I, Plevkova J, Buday T. Retrospective Study of Factors Potentially Influencing Occurrence of Cough in Slovak Patients with Sarcoidosis. Can Respir J 2019; 2019: 3808206.
30. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120: 102–08.
31. Barreiro TJ, Perillo I. An approach to interpreting spirometry. Am Fam Physician 2004; 69 (5): 1107–14.
32. Sharp M, Psoter KJ, Balasubramanian A, Pulapaka AV, Chen ES, Brown SAW, et al. Heterogeneity of lung function phenotypes in sarcoidosis: role of race and sex differences. Ann Am Thorac Soc 2023; 20 (1): 30–7.
33. Sève P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells 2021; 10 (4): 766. doi: 10.3390/cells10040766.
Objavljeno
2025/01/21
Broj časopisa
Vol. 44 Br. 3 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Branislav Gvozdenovic, Violeta Mihailovic-Vucinic, Mira Vukovic, Maja Omcikus, Jelena Cvejic, Slobodan Belic, Jelena Jankovic, Natasa Djurdjevic, Mihailo Stjepanovic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.